• PR-619: Advancing DUB Inhibition for Next-Gen Translational

  2026-04-30

  This thought-leadership article explores the mechanistic and translational relevance of PR-619, a broad-spectrum deubiquitylating enzymes inhibitor, providing strategic insights for researchers navigating the complexities of ubiquitination pathway research in cancer and neurodegenerative disease models. By integrating protocol guidance, competitive analysis, and clinical context, it equips scientists to harness PR-619 for high-impact discovery and translational applications.

• Angiotensin II: Technical Guidance for Vascular Research Use

  2026-04-30

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a reference octapeptide for modeling hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy. This guide details actionable preparation, dosing, and troubleshooting strategies to optimize research utility. Use is restricted to controlled scientific settings and not for diagnostic or therapeutic applications.

• Talabostat mesylate (PT-100): Applied Workflows in Tumor Mic

  2026-04-29

  Talabostat mesylate (PT-100) empowers researchers to dissect the tumor microenvironment by precisely inhibiting DPP4 and FAP activity, with workflow flexibility from in vitro cytotoxicity studies to in vivo tumor modulation. This article delivers protocol-driven insights, troubleshooting strategies, and translational guidance for maximizing experimental reliability using APExBIO’s validated compound.

• WEHI-539: Dissecting BCL-XL Dependency in Cancer Stem Cells

  2026-04-29

  Explore the unique selectivity of WEHI-539 as a BCL-XL inhibitor and its pivotal role in apoptosis research and cancer stem cell sensitization. This article delivers an advanced, evidence-based perspective on leveraging WEHI-539 for mechanistic studies and therapeutic innovation.

• AT-406 (SM-406): Optimizing Apoptosis Pathway Activation in

  2026-04-28

  AT-406 (SM-406) stands out as a potent, orally bioavailable IAP antagonist that reliably induces apoptosis in cancer cells and sensitizes them to chemotherapeutics. This guide delivers actionable workflow enhancements, protocol parameters, and troubleshooting strategies for maximizing AT-406's impact in translational oncology research.

• Cell Surface Integrity Limits Ploidy in Budding Yeast

  2026-04-28

  Barker et al. reveal that the maximum ploidy achievable by Saccharomyces cerevisiae is constrained by cell surface integrity, with physical factors modulating this upper limit. Their work provides mechanistic insight into how increases in genomic DNA and cell size stress the plasma membrane, linking ploidy to gene repression in ergosterol biosynthesis and offering new perspectives for antifungal research.

• Nano-Delivery System Targets P. aeruginosa to Accelerate Wou

  2026-04-27

  This study presents a targeted nano-delivery system combining antibiotics and photodynamic therapy to combat Pseudomonas aeruginosa infections in wounds. The approach demonstrates enhanced antibacterial and anti-biofilm efficacy, leading to improved healing outcomes with minimal toxicity.

• Topotecan as a Topoisomerase I Inhibitor in Cancer Therapy

  2026-04-27

  This review analyzes the pharmacological profile of topotecan, a semisynthetic topoisomerase I inhibitor with demonstrated efficacy in small cell lung and ovarian cancers. The study details its unique DNA-targeting mechanism, clinical pharmacokinetics, toxicity, and positions topotecan in the evolving landscape of combination chemotherapy.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Deep Dive Into Proteasome Inh

  2026-04-26

  Explore how MG-262 (Z-Leu-Leu-Leu-B(OH)2) advances proteasome inhibition assays and skeletal muscle research. This article uniquely bridges chaperone-mediated autophagy insights with practical guidance for apoptosis and cell cycle studies.

• Evaluating Drug Responses in Cancer: Innovations in In Vitro

  2026-04-25

  This dissertation introduces advanced in vitro methods to distinguish and quantify cancer drug effects on cell death versus proliferation arrest, challenging standard viability assessment practices. The findings provide a nuanced framework to improve the predictive value of preclinical anti-cancer drug testing, with implications for optimizing experimental workflows.

• STING agonist-1: Empowering Innate Immunity Assays

  2026-04-24

  STING agonist-1 stands out as a high-purity, DMSO-soluble small molecule for rigorous activation of the STING pathway in both immunology and cancer research. Its role in dissecting B cell-driven antitumor responses and tertiary lymphoid structure formation enables advanced experimental workflows and translational insights.

• Caspase 3/7 Regulate Cytoprotective Autophagy in Breast Canc

  2026-04-24

  This study uncovers a previously unappreciated role for caspase 3 and caspase 7 in supporting cytoprotective autophagy and DNA damage response during non-lethal stress in human breast cancer cells. These findings reshape our understanding of effector caspases beyond apoptosis, with implications for cancer therapy design and experimental modeling.

• ZNF706 as a Diagnostic and Therapeutic Target in HCC

  2026-04-23

  This study establishes Zinc Finger Protein 706 (ZNF706) as a clinically relevant biomarker and putative therapeutic target in hepatocellular carcinoma (HCC). Through integrated bioinformatics and experimental validation, the authors show that ZNF706 overexpression correlates with tumor progression and poor prognosis, supporting its candidacy for biotechnological assay development and targeted intervention.

• O-GlcNAcylation Regulates HUWE1-TfR1 Axis in Preeclampsia Fe

  2026-04-23

  This study uncovers how O-GlcNAc modification stabilizes the E3 ligase HUWE1, promoting ubiquitination and degradation of transferrin receptor 1 (TfR1) to limit iron uptake and ferroptosis in trophoblasts. The findings position O-GlcNAc–HUWE1–TfR1 signaling as a central mechanism in preeclampsia pathogenesis and a promising therapeutic target.

• A1 Astrocyte Activation Drives Microglial Polarization via p

  2026-04-22

  This study elucidates how A1 reactive astrocytes, activated by 2-chloroethanol, drive M1 microglia polarization through upregulation of IL-1β and TNF-α, mediated by the p38 MAPK/NF-κB and AP-1 pathways. These findings clarify astrocyte–microglia crosstalk in neuroinflammation and highlight pathway-specific intervention points for inflammation research.

16654 records 1/1111 page Next 12345 下5页 Last page